DAM
DMAAR

DLD Asset Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

DLD Asset Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.14K Hold
101,594
– – ﹤0.01% 353
2025
Q4 		$19K Buy
+101,594
New +$19.7K ﹤0.01% 351

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

DLD Asset Management's DMAAR Position: Q1 2026 in Review

DLD Asset Management held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q1 2026 at 101,594 shares worth $6.14K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

DLD Asset Management first reported a position in DMAAR in Q4 2025 and has held it in 2 quarters since. The position peaked at $19K in Q4 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • DLD Asset Management held 101,594 shares of Drugs Made In America Acquisition Corp Rights worth $6.14K as of Q1 2026.
  • DLD Asset Management left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of DLD Asset Management's portfolio in Q1 2026, its #353 holding.
  • DLD Asset Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q4 2025 and has held it in 2 quarters since.
  • DLD Asset Management's Drugs Made In America Acquisition Corp Rights position peaked at $19K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on DLD Asset Management's 13F filing for Q1 2026, filed 13 May 2026.